Concert Pharmaceuticals (NASDAQ: CNCE) will present clinical data on CTP-543 for treating alopecia areata at the 29th EADV Virtual Congress from October 29-31, 2020. The presentation will share results from an ongoing open-label extension study, focusing on the long-term safety and treatment effects of CTP-543. This oral selective inhibitor of Janus kinases has received Breakthrough Therapy and Fast Track designations from the FDA. The Company plans to initiate Phase 3 evaluation of CTP-543 in Q4 2020.
Concert Pharmaceuticals (NASDAQ: CNCE) has completed patient enrollment for its Phase 2 clinical trial of CTP-692, an adjunctive treatment for schizophrenia. The trial aims to assess the drug's effectiveness in improving primary symptom domains, including both positive and negative symptoms, as well as cognitive function. A total of 325 patients were randomized to receive varying doses of CTP-692 or a placebo. Topline data is expected in Q1 2021, with a focus on changes in the Positive and Negative Syndrome Scale (PANSS) total score after 12 weeks of treatment.